KalVista Pharmaceuticals, Inc.
NASDAQ:KALVBiotechnology
+$0.00 today
- Market cap
- $1.44B
- Beta
- -0.11
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$2.74
Volume 4.26M
Average 3.47M
Income Statement
Follow revenue through to earnings.
Revenue
$73.62M
FY 2026 · Annual
Operating Income
-$171.84M
FY 2026 · Annual
Net Income
-$164.29M
FY 2026 · Annual
Income Statement
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 73.62M |
| Cost of Revenue | 0 | 0 | 86.17M | 0 | 6.08M |
| Gross Profit | 0 | 0 | (86.17M) | 0 | 67.54M |
| Gross Margin | — | — | — | — | 91.7% |
| Research & Development | 70.17M | 80.28M | 86.17M | 71.71M | 55.64M |
| Selling, General & Admin | 26.45M | 30.6M | 54.28M | 116.29M | 183.74M |
| Operating Expenses | 96.61M | 110.87M | 54.28M | 188M | 239.38M |
| Depreciation & Amortization | 564K | 718K | 816K | 941K | 1.45M |
| EBITDA | (80.75M) | (94.37M) | (134.28M) | (173.33M) | (150.62M) |
| EBITDA Margin | — | — | — | — | -204.6% |
| Operating Income | (96.61M) | (110.87M) | (140.45M) | (188M) | (171.84M) |
| Operating Margin | — | — | — | — | -233.4% |
| Interest Income | 1.09M | 2.23M | 3.9M | 6.44M | 8.68M |
| Interest Expense | 0 | 0 | 0 | 5.79M | 19.34M |
| Other Income / Expenses | 14.27M | 17.96M | 5.35M | 7.94M | 420K |
| Income Before Tax | (82.34M) | (92.91M) | (135.1M) | (180.05M) | (171.42M) |
| Pre-Tax Margin | — | — | — | — | -232.9% |
| Income Tax Expense | 0 | 0 | (8.45M) | 3.39M | (7.13M) |
| Net Income | (82.34M) | (92.91M) | (126.64M) | (183.44M) | (164.29M) |
| Net Margin | — | — | — | — | -223.2% |
| EPS (Basic) | (3.36) | (3.33) | (3.44) | (3.69) | (3.23) |
| EPS (Diluted) | (3.36) | (3.33) | (3.44) | (3.69) | (3.23) |
| 24.47M | 27.89M | 36.79M | 49.65M | 50.9M | |
| 24.47M | 27.89M | 36.79M | 49.65M | 50.9M |
KALV Earnings Waterfall · TTM
NASDAQ:KALV · Revenue to Net Income
Key Ratios
Analysis
$115.9M of revenue converted into -$138.4M of net income for the selected period. Gross margin is 83.6% and net margin is -1160.5%, showing how much revenue survives after costs and taxes. EPS is $-3.23, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Jun 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 11, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 11, 2026 |
How much revenue does KALV generate?
KalVista Pharmaceuticals, Inc. (KALV) reported $73.62M of revenue in fiscal 2026.
Is KALV profitable?
KalVista Pharmaceuticals, Inc. (KALV) reported -$164.29M of net income, with a net margin of -223.2%.
Continue the stock analysis
Jump to another research area for this company.